Adnan Nasir MD

Dermatology•Raleigh, NC

Physician

Join to View Full Profile

4414 Lake Boone TrlWake Dermatology, Suite 408Raleigh, NC 27607
Phone+1 919-781-1001
Fax+1 919-781-3909

Education & Training

University of North Carolina HospitalsResidency, Dermatology, 1996 - 1999
Mass General Brigham/Massachusetts General HospitalInternship, Internal Medicine, 1995 - 1996
University of Rochester School of Medicine and DentistryClass of 1995

Certifications & Licensure

NC State Medical License 1996 - 2025
American Board of Dermatology Dermatology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Top MD Consumers Checkbook
Fellow (FAAD) American Academy of Dermatology

Clinical Trials

Efficacy and Safety Phase II Study of SR-T100 to Treat Actinic Keratosis Start of enrollment: 2013 Feb 01
Completed
Phase 2
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis Start of enrollment: 2013 Nov 01
Completed
Phase 3
A Study of Multiple Doses of AbGn-168H by Intravenous Infusion in Patients With Moderate to Severe Chronic Plaque Psoriasis Start of enrollment: 2014 May 01
Completed
Phase 2
Efficacy and Tolerability of New Topical Formulations in Subjects With Atopic Dermatitis Start of enrollment: 2016 Mar 01
Completed
Phase 4
Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis Start of enrollment: 2016 Apr 27
Completed
Phase 1
Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity Start of enrollment: 2017 Feb 10
Completed
Phase 2
A Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis Start of enrollment: 2017 Sep 21
Completed
Phase 1
8-Week Atopic Dermatitis (AD) Treatment Study Start of enrollment: 2017 Nov 27
Completed
Phase 3
Cantharidin and Occlusion in Verruca Epithelium Start of enrollment: 2018 Mar 27
COMPLETED
PHASE2
A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD Start of enrollment: 2018 Apr 27
Terminated
Phase 4
A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis Start of enrollment: 2018 Jun 27
Terminated
Phase 3
A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic Dermatitis Start of enrollment: 2019 May 30
Completed
Phase 1
A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19 Start of enrollment: 2020 Jul 27
Completed
Phase 3
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 Start of enrollment: 2020 Dec 27
Completed
Phase 3
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) Start of enrollment: 2019 Oct 03
Completed
Phase 3
A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata Start of enrollment: 2019 Jul 08
COMPLETED
PHASE3
Join now to see all

Publications & Presentations

PubMed

80 citations
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.
Jonathan I Silverberg, Emma Guttman-Yassky, Diamant Thaçi, Alan D Irvine, Linda Stein Gold
The New England Journal of Medicine. 2023-03-23
84 citations
Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo.
David Rosmarin, Thierry Passeron, Amit G Pandya, Pearl Grimes, John E Harris
The New England Journal of Medicine. 2022-10-20
203 citations
Two Phase 3 Trials of Baricitinib for Alopecia Areata.
Brett King, Manabu Ohyama, Ohsang Kwon, Abraham Zlotogorski, Justin Ko
The New England Journal of Medicine. 2022-05-05

Journal Articles

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
E.L. Simpson, New England Journal of Medicine, 12/15/2016
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
Gilbert PB et al, Science, 1/7/2022
Phase 3 Trials of Ixekizumab in Moderate to Severe Plaque Psoriasis
K.B. Gordon et. al., New England Journal of Medicine, 6/8/2016

Lectures

Clinical Trials in Dermatology
American Academy of Dermatology - Annual Meeting 2019 - Washington, D.C. - 3/3/2019

Press Mentions

Don't Blame Creatine for Hair LossMay 18th, 2021
The Best Ways to Treat Sunburned LipsJune 18th, 2020
Nanodermatology-Based Solutions for Psoriasis: State-of-The Art and Future ProspectsNovember 1st, 2019
Join now to see all